Research programme: HIV protease inhibitors - GlaxoSmithKline/Vertex
Latest Information Update: 24 Oct 2021
At a glance
- Originator GlaxoSmithKline; Vertex Pharmaceuticals
- Class
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 01 Jun 2004 Data presented at the 17th International Conference on Antiviral Research (ICAR-2004) have been added to the Viral infections pharmacodynamics section
- 09 Aug 2002 This programme is still in active development
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline